Overview

Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients who have stage IIB, stage IVA, or stage IVB recurrent or refractory mycosis fungoides.

Phase:

Phase 2

Details

Lead Sponsor:

European Organisation for Research and Treatment of Cancer - EORTC

Treatments:

Doxorubicin
Liposomal doxorubicin